Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular
complication has been less carefully investigated than the risk of cardiovascular mortality …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown impressive effects
in reducing major vascular events in several randomized controlled trials (RCTs). The …

Background There is still a lack of research on which diabetic drugs are more effective in
preventing stroke. Our network metaanalysis aimed to compare cerebrovascular benefits …

Aims People with diabetes tend to face a higher risk of stroke. Randomized controlled trials
(RCTs) have demonstrated the different outcomes of new glucose-lowering drugs marketed …

Context The effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on
ischemic/hemorrhagic stroke and transient ischemic attacks (TIA) in type 2 diabetes mellitus …

The effects of sodium‐glucose cotransporter 2 (SGLT2) inhibitors on risk of stroke have not
been conclusively established. Therefore, we conducted a meta‐analysis to evaluate the …

Background Randomized controlled clinical trials (RCT) have demonstrated varied efficacy
of glucagon-like peptide-1 receptor (GLP-1R) agonists for cardiovascular outcomes. We …

Stroke is a leading cause of disability and death, and people with type 2 diabetes (T2D)
have a greater risk of stroke and death or disability from stroke. The underlying …

Despite Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been associated with a
reduced risk of heart failure in patients with type 2 diabetes mellitus (T2DM), the effect …

Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people
without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke …